R G Miller1, L Yu2, D J Becker3, T J Orchard1, T Costacou1. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. 2. School of Medicine, Barbara Davis Center, University of Colorado Denver, Aurora, CO, USA. 3. Department of Paediatrics, Division of Pediatric Endocrinology and Diabetes, University of Pittsburgh, Pittsburgh, PA.
Abstract
AIMS: To examine the association between islet autoantibody positivity and clinical characteristics, residual β-cell function (C-peptide) and prevalence of complications in a childhood-onset (age <17 years), long-duration (≥32 years) type 1 diabetes cohort. METHODS: Islet autoantibodies (glutamic acid decarboxylase, insulinoma-associated protein 2 and zinc transporter-8 antibodies) were measured in the serum of participants who attended the 2011-2013 Pittsburgh Epidemiology of Diabetes Complications study follow-up examination (n=177, mean age 51 years, diabetes duration 43 years). RESULTS: Prevalences of islet autoantibodies were: glutamic acid decarboxylase, 32%; insulinoma-associated protein 2, 22%; and zinc transporter-8, 4%. Positivity for each islet autoantibody was associated with older age at diabetes onset (glutamic acid decarboxylase antibodies, P=0.03; insulinoma-associated protein 2 antibodies, P=0.001; zinc transporter-8 antibodies, P<0.0001). Older age at onset was also associated with an increasing number of autoantibodies (P = 0.001). Glutamic acid decarboxylase antibody positivity was also associated with lower HbA1c (P = 0.02), insulinoma-associated protein 2 antibody positivity was associated with lower prevalence of severe hypoglycaemic episodes (P=0.02) and both distal and autonomic neuropathy (P=0.04 for both), and zinc transporter-8 antibody positivity was associated with higher total and LDL cholesterol (P=0.01). No association between autoantibody positivity and C-peptide was observed. CONCLUSIONS: The strong association between islet autoantibody positivity and older age at type 1 diabetes onset supports the hypothesis of a less aggressive, and thus more persistent, immune process in those with older age at onset. This observation suggests that there may be long-term persistence of heterogeneity in the underlying autoimmune process.
AIMS: To examine the association between islet autoantibody positivity and clinical characteristics, residual β-cell function (C-peptide) and prevalence of complications in a childhood-onset (age <17 years), long-duration (≥32 years) type 1 diabetes cohort. METHODS: Islet autoantibodies (glutamic acid decarboxylase, insulinoma-associated protein 2 and zinc transporter-8 antibodies) were measured in the serum of participants who attended the 2011-2013 Pittsburgh Epidemiology of Diabetes Complications study follow-up examination (n=177, mean age 51 years, diabetes duration 43 years). RESULTS: Prevalences of islet autoantibodies were: glutamic acid decarboxylase, 32%; insulinoma-associated protein 2, 22%; and zinc transporter-8, 4%. Positivity for each islet autoantibody was associated with older age at diabetes onset (glutamic acid decarboxylase antibodies, P=0.03; insulinoma-associated protein 2 antibodies, P=0.001; zinc transporter-8 antibodies, P<0.0001). Older age at onset was also associated with an increasing number of autoantibodies (P = 0.001). Glutamic acid decarboxylase antibody positivity was also associated with lower HbA1c (P = 0.02), insulinoma-associated protein 2 antibody positivity was associated with lower prevalence of severe hypoglycaemic episodes (P=0.02) and both distal and autonomic neuropathy (P=0.04 for both), and zinc transporter-8 antibody positivity was associated with higher total and LDL cholesterol (P=0.01). No association between autoantibody positivity and C-peptide was observed. CONCLUSIONS: The strong association between islet autoantibody positivity and older age at type 1 diabetes onset supports the hypothesis of a less aggressive, and thus more persistent, immune process in those with older age at onset. This observation suggests that there may be long-term persistence of heterogeneity in the underlying autoimmune process.
Authors: T J Orchard; J S Dorman; R E Maser; D J Becker; D Ellis; R E LaPorte; L H Kuller; S K Wolfson; A L Drash Journal: Diabetes Care Date: 1990-07 Impact factor: 19.112
Authors: T J Orchard; J S Dorman; R E Maser; D J Becker; A L Drash; D Ellis; R E LaPorte; L H Kuller Journal: Diabetes Date: 1990-09 Impact factor: 9.461
Authors: Pia Leete; Abby Willcox; Lars Krogvold; Knut Dahl-Jørgensen; Alan K Foulis; Sarah J Richardson; Noel G Morgan Journal: Diabetes Date: 2016-02-08 Impact factor: 9.461
Authors: A Lernmark; G Klöppel; D Stenger; C Vathanaprida; K Fält; M Landin-Olsson; D G Baskin; J P Palmer; A M Gown; J S Petersen Journal: Virchows Arch Date: 1995 Impact factor: 4.064
Authors: Janet M Wenzlau; Kirstine Juhl; Liping Yu; Ong Moua; Suparna A Sarkar; Peter Gottlieb; Marian Rewers; George S Eisenbarth; Jan Jensen; Howard W Davidson; John C Hutton Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Carolyn C Richardson; James A Dromey; Kerry A McLaughlin; Diana Morgan; H Jonathan Bodansky; Richard G Feltbower; Anthony H Barnett; Geoffrey V Gill; Steven C Bain; Michael R Christie Journal: Diabetologia Date: 2013-08-20 Impact factor: 10.122
Authors: Richard A Oram; Angus G Jones; Rachel E J Besser; Bridget A Knight; Beverley M Shields; Richard J Brown; Andrew T Hattersley; Timothy J McDonald Journal: Diabetologia Date: 2014-01 Impact factor: 10.122
Authors: I G Gvazava; A V Kosykh; O S Rogovaya; O P Popova; K A Sobyanin; A C Khrushchev; A V Timofeev; E A Vorotelyak Journal: Acta Naturae Date: 2020 Oct-Dec Impact factor: 1.845